Odyssey Group International Inc. ODYY Archives - Page 4 of 7

ThursdayAug 25, 2022 10:30 am

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients The company reported completion of four cohorts of testing for safety in human subjects in August, and is preparing to launch Phase II testing that will evaluate the product’s efficacy PRV-002 is administered intranasally where it can be taken up across the blood-brain barrier by…

MondayAug 22, 2022 9:00 am

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing (“SAD”) clinical trial The MAD arm thus far shows that the drug is safe and well tolerated Odyssey expects to report additional MAD results as they become available A few weeks after completing its Phase I Single Ascending Dosing (“SAD”) clinical trial, Odyssey Health (OTC:…

ThursdayAug 18, 2022 11:07 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, has completed safety measures for its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to study PRV-002, the company’s proprietary drug to treat concussion; this phase involves healthy human subjects. The company noted that the MAD cohort I, which was conducted at Nucleus Network, a leading clinical research organization, indicated the drug was safe and well tolerated. That phase involved eight healthy human volunteers who…

TuesdayAug 16, 2022 2:12 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured on “Dr. Finance Live,” a podcast series focused on changing the way we think about economics and finance. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the recent broadcast, hosted by best-selling author and entrepreneur Dr. Anthony M. Criniti IV (aka “Dr. Finance(R)”). During the interview, Favre discussed how his passion for uncovering a treatment for concussion led him to his current position as a member of Odyssey Health’s sports advisory board. “When I retired…

ThursdayAug 11, 2022 11:50 am

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, is sharing an interview by NFL Hall of Famer Brett Favre. During the interview, hosted by Bubba, the Love Sponge(R), Favre talks about the many concussions he received while playing football. Earlier this week, Favre did another interview with ODYY head of drug development Dr. Jacob VanLandingham, in which he also talked about concussions. During the interview with Bubba, the Love Sponge, Favre explained that when he left the NFL years ago, he…

ThursdayAug 11, 2022 9:30 am

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladies The company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteers Odyssey Health recently announced a redesign of its website and an update of its corporate presentation to better communicate its efforts and allow interested investors to access information regarding the company The website redesign follows on the company’s name change earlier this year to similarly improve the expression of its brand identity Medical technology…

WednesdayAug 10, 2022 12:27 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (“MAD”) arm for its phase I clinical trial. The trial is administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. According to the update, MAD Cohort I subjects were dosed for five consecutive days, with the drug, PRV-002, safe and well tolerated. “As the head of drug development for the PRV-002 concussion treatment, I was very happy to see these positive safety results when dosing for multiple days,” said…

TuesdayAug 09, 2022 12:48 pm

QualityStocksNewsBreaks – Odyssey Health Inc.’s (ODYY) Dr. Jacob VanLandingham, Brett Favre Featured in ‘Get Authentic’ Podcast

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent episode of Get Authentic with Marques Ogden, a podcast series delivering honest, unfiltered and real-time stories from legendary athletes and industry leaders. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the program, where Dr. VanLandingham discussed the unique selling proposition of Odyssey’s development pipeline. Favre also discussed the last days of his NFL career and his focus as a member of Odyssey’s sports advisory board. “My last play [in the NFL] was…

ThursdayAug 04, 2022 12:06 pm

QualityStocksNewsBreaks – Odyssey Health Inc. (ODYY) Unveils New Corporate Website

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the launch of its new corporate website. Consistent with the company’s recent name change, the new website was designed to better reflect Odyssey Health’s mission and focus while also improving communication strategies with current and potential shareholders, institutions, and various scientific and financial publications. “The launch of our new website is an important next step in the ongoing evolution of Odyssey and will enable us to provide more transparent communications with our shareholders and other stakeholders,” said Odyssey Health CEO Michael Redmond. “We are excited…

ThursdayAug 04, 2022 10:30 am

Odyssey Health, Inc. (ODYY) Drug Product Testing Aims to Give Military Veterans New Weapon for Fighting Brain Injury

The medical care needs of military personnel are once again in the spotlight following a political dust-up over service members’ exposure to environmental hazards at burn pits Another long-standing concern among service personnel is the treatment of concussive brain injuries Although no FDA-approved prescription drug currently exists for treating concussions, medical product developer Odyssey Health Inc. is testing a device-drug combination designed to stop concussion injury in its tracks to avoid long-term harm Odyssey Health’s product would use an inhaler-like device to deliver the special medication into the nasal cavity for better uptake into the central nervous system, keying on…

Site Search

Company Search

Tag: Odyssey Group International Inc. ODYY